Transdermal Patch Hydrophobic Colloidal Silica Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Transdermal patches with low-melting or highly diffusible drugs face issues such as delamination, cold flow, and drug diffusion due to changes in the active pharmaceutical ingredient's physical form during processing, leading to instability and ineffective drug delivery.
Innovation Solution
Incorporating hydrophobic colloidal silica as an excipient in the transdermal system to adsorb drug molecules, controlling the drug delivery rate and physical performance by laminating an adhesive layer with varying thickness to a drug reservoir layer containing polyisobutylene, mineral oil, and hydrophobic colloidal silica, which effectively prevents drug diffusion and maintains stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If a low-melting point active pharmaceutical ingredient is added to an adhesive composition and subjected to heat or pressure during extrusion, then the drug can be incorporated into the adhesive layer, but the drug melts and solidifies in a different physical form (amorphous or crystalline polymorph) which affects transdermal system performance
Solution Approach 1:
The patent controls the physical form of the active pharmaceutical ingredient by carefully managing processing parameters (temperature and pressure during extrusion) to prevent unwanted melting and polymorphic changes, while still achieving adequate drug incorporation into the adhesive layer
Solution Approach 2:
The patent uses a composite adhesive composition containing the active pharmaceutical ingredient, adhesive polymer, and other excipients formulated to maintain drug stability during processing. The composite structure allows the drug to be incorporated while protecting its physical form through the matrix
2Ease of manufacture
If the active pharmaceutical ingredient converts from solid state to oil state during processing, then the drug can be dispersed in the adhesive matrix, but the oil state plasticizes the adhesive matrix causing delamination and cold flow
Solution Approach 1:
The patent maintains the active pharmaceutical ingredient in its solid state during processing by controlling temperature and pressure parameters, preventing conversion to oil state. This avoids plasticization of the adhesive matrix while still achieving adequate dispersion through the solid-state drug particles
Solution Approach 2:
The patent uses short-chain polyisobutylene as a plasticizer alternative that provides necessary matrix flexibility without causing the harmful plasticization effects associated with oil-state drugs. This short-chain polymer serves as a stable, non-migrating plasticizing agent
3Ease of manufacture
If the active pharmaceutical ingredient is in oil form and not sufficiently adsorbed, then the drug can be dispersed through the matrix, but the oil diffuses through the matrix causing film deposition and delamination
Solution Approach 1:
The patent changes the physical state parameter of the active pharmaceutical ingredient from oil form to solid form, preventing diffusion through the adhesive matrix. The solid-state drug remains dispersed as particles rather than migrating as a liquid, eliminating film deposition issues
Solution Approach 2:
The patent creates localized drug distribution throughout the adhesive matrix as solid particles rather than uniform oil dispersion. This localized solid-state distribution prevents the continuous diffusion pathway that would lead to film deposition at the release liner interface
4Productivity
If the adhesive layer serves as a rate-limiting layer to control diffusion of oily drugs, then drug diffusion can be controlled, but this requires the drug to be in oil form which causes plasticization and delamination issues
Solution Approach 1:
The patent changes the drug delivery rate control mechanism from relying on oil-form drug diffusion through the adhesive layer to controlling release of solid-state drug particles. The rate-limiting function is achieved through the adhesive matrix structure and composition rather than through diffusion of liquid drug
Solution Approach 2:
The patent uses short-chain polyisobutylene to modify the adhesive matrix properties, creating a rate-limiting barrier that controls drug release without requiring the drug to be in oil form. This provides both stability and controlled delivery functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of hydrophobic colloidal silica in transdermal patches enhances the stability and controlled release of drugs, reducing delamination and cold flow issues, while ensuring uniform distribution and adsorption of drug molecules, thereby improving the overall performance and stability of the transdermal system.
Implementation Method 1
Incorporating hydrophobic colloidal silica as an excipient in the transdermal system to adsorb drug molecules
Data Source
AI summary
A drug-containing patch allows transdermal administration of a drug. The patch features a hydrophobic reservoir containing the drug, where the reservoir has a first surface and a second surface. A drug-impermeable backing overlies the first surface of the reservoir. A release sheet may overlie the second surface of the reservoir. The hydrophobic reservoir contains a drug and a hydrophobic matrix, where the hydrophobic matrix includes a hydrophobic filler in an amount which is effective to adsorb said drug; and a mixture of polyisobutylene and mineral oil. The hydrophobic matrix may contain hydrophobic colloidal silica as the hydrophobic filler. The hydrophobic reservoir layer may serve as a skin-contacting adhesive layer. Alternatively, a release-controlling adhesive layer may serve as the skin-contacting adhesive layer. The release-controlling adhesive layer may contain hydrophobic colloidal silica and a mixture of polyisobutylene and mineral oil.